Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.02 – $3.50
0% from low
Exchange
OTC Link
OTHER
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24.92B | $28.59B | $30.31B | $39.01B | $43.95B | $41.40B | $41.07B | $40.43B |
| Cost of revenue | $10.37B | $11.54B | $13.43B | $20.23B | $23.17B | $21.60B | $21.37B | $20.26B |
| Gross profit | $14.55B | $17.04B | $16.88B | $18.78B | $20.78B | $19.80B | $19.70B | $20.16B |
| Gross margin | 58.4% | 59.6% | 55.7% | 48.1% | 47.3% | 47.8% | 48.0% | 49.9% |
| R&D | $1.48B | $2.04B | $2.80B | $3.83B | $4.30B | $4.35B | $3.64B | $3.91B |
| Operating income | $3.54B | $6.41B | $4.72B | $6.31B | $8.30B | $3.31B | $4.25B | $2.54B |
| EBITDA | $4.54B | $7.07B | $7.29B | $8.81B | $7.87B | $5.56B | $8.60B | $6.16B |
| Net income | $2.71B | $3.32B | $3.66B | $4.73B | $3.73B | $2.39B | $2.77B | $3.28B |
| Net margin | 10.9% | 11.6% | 12.1% | 12.1% | 8.5% | 5.8% | 6.7% | 8.1% |
| EPS (diluted) | 1.07 | 1.30 | 1.43 | 1.85 | 1.43 | 0.89 | 1.04 | 1.26 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $45.0B | $1.52 | $1.44–$1.59 | 1 |
| 2027 | $46.7B | $1.73 | $1.64–$1.81 | 1 |
| 2028 | $49.5B | $1.94 | $1.84–$2.03 | 1 |
Forward consensus · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| SFOSFShanghai Fosun Pharmaceutical (Group) Co., Ltd. | $2.02 | +0.00% | $5.3B | — |
| BDULFBangkok Dusit Medical Services Public Company Limited | $0.56 | +0.00% | $8.9B | — |
| BDUUFBangkok Dusit Medical Services Public Company Limited | $0.64 | +0.00% | $10.2B | — |
| BIOVFSwedish Orphan Biovitrum AB (publ) | $48.00 | +0.00% | $16.6B | — |
| CSPCYCSPC Pharmaceutical Group Limited |
SHANGHAI FOSUN PHARM REG
No one on the platform currently holds SFOSF.
No tracked institution reports a position in SFOSF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-20 | $0.4500 | 2026-08-14 |
| 2025-07-28 | $0.3500 | 2025-08-22 |
| 2024-07-30 | $0.3000 | 2024-08-23 |
| 2023-08-01 | $0.4600 | 2023-08-24 |
No one on the platform has traded SFOSF yet.
| $3.51 |
| +6.98% |
| $10.1B |
| — |
| ESAIYEisai Co., Ltd. | $6.31 | +0.64% | $7.1B | — |
| ESALFEisai Co., Ltd. | $25.00 | +0.00% | $7.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.9× earnings vs its 2.4× historical median P/E.
Fair value ≈ $2.48 · price $2.02 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.